By Chris Wack


Pieris Pharmaceuticals Inc. shares were up 19% to $4.21 Thursday after the company said the U.S. Food and Drug Administration has granted orphan drug designation to cinrebafusp alfa for the treatment of HER2-high and HER2-low expressing gastric cancers.

The biotechnology company said it expects to begin the Phase 2 trial of cinrebafusp alfa, a 4-1BB/HER2 bispecific, later this summer.

Volume for the stock was 23 million shares at 1:30 p.m. ET, compared with a 65-day average volume of 9.4 million shares. The stock hit a 52-week high of $5.09 on May 26.

The FDA grants orphan drug designation to promote the development of a drug that targets a condition affecting 200,000 or fewer U.S. patients annually.

Orphan drug designation provides qualifying therapies with development and commercial incentives, including FDA assistance in clinical trial design, tax credits for eligible clinical trials, waiver of application fees, and market exclusivity for seven years following FDA approval, in addition to other available regulatory exclusivities.


Write to Chris Wack at


(END) Dow Jones Newswires

June 24, 2021 13:52 ET (17:52 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.